Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ponesimod

- PMLiVE

Xarelto uses extended in US

New FDA approval could be huge sales boost for Bayer's and J&J's anticoagulant

- PMLiVE

Sales rise but profits fall at J&J in Q3

Failed clinical programmes and Synthes acquisition hit net results

Novartis building

Gilenya cuts early relapse, brain loss in MS patients

Boosts prospects for oral drug as competitors emerge

European approvals for J&J cancer treatments

EC passes new Dacogen indications and backs subcutaneous Velcade

J&J files intravenous Simponi formulation in US

FDA approval would complement J&J’s current subcutaneously-administered product

- PMLiVE

J&J to launch ‘innovation centres’ in US, UK and China

Will target local life sciences partnerships in early-stage innovation

J&J appoints Bayer’s Sandra Peterson as group worldwide chair

Will have responsibility for troubled consumer goods division

- PMLiVE

FDA clears Sanofi’s oral MS drug Aubagio

Will compete with Novartis’ Gilenya

Amgen poaches J&J’s Ray Jordan for corporate affairs post

He joins on October, 1 with a strategic communications remit

- PMLiVE

J&J responds to FDA concerns over Xarelto in ACS

Responds to regulator about missing clinical trial data

- PMLiVE

J&J signs $1.1bn deal with Genmab for cancer antibody

Licenses daratumumab in development for multiple myeloma

- PMLiVE

End of the line for intravenous bapineuzumab in Alzheimer’s

Negative trial results for Pfizer and Johnson & Johnson to concede defeat

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links